Details of Disease

General Information of Disease (ID: DISA7ZGL)

Disease Name	Uveal Melanoma
Synonyms	choroidal melanoma; iris melanoma; melanoma, uveal, malignant; intraocular melanoma; melanoma (disease) of uvea; melanoma of uvea; uveal melanoma; uvea melanoma; uvea melanoma (disease); melanoma of the uvea
Disease Class	2D0Y: Uveal Melanoma
Definition	A melanoma derived from melanocytes of the uveal tract. It is the most common primary intraocular tumor in the United States and Western Europe. Similar to melanoma of the skin, it is rare in Africa and Asia. Diagnostic procedures include ophthalmoscopic exam, fluorescein angiography and ultrasound. Treatment includes: surgical excision of the eye, iridocyclectomy and tumor resection. Recent treatments also include radiotherapy or photo coagulation. Classification of uveal melanomas recognizes four cell types within these tumors: epithelioid, intermediate, mixed cell, and spindle cell types. The spindle cell type uveal melanomas are further sub-classified as spindle cell type A and spindle cell type B.
Disease Hierarchy	DIS1RRCY: Melanoma DISOHHFC: Ocular melanoma DISWEI2N: Uveal cancer DISA7ZGL: Uveal Melanoma
ICD Code	ICD-11 ICD-11: 2D0Y
Disease Identifiers	MONDO ID MONDO_0006486 MESH ID C536494 UMLS CUI C0220633 OMIM ID 155720 MedGen ID 65077 HPO ID HP:0007716 Orphanet ID 39044

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hepzato	DM2AZPP	Phase 3	NA	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 42 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACKR3	TTRQJTC	Limited	Genetic Variation	[2]
CACNA2D1	TTFK1JQ	Limited	Genetic Variation	[3]
MAP2K7	TT6QY3J	Limited	Biomarker	[4]
TYR	TTULVH8	Limited	Altered Expression	[5]
MLANA	TT362RB	Disputed	Biomarker	[6]
CD160	TTOFEAS	moderate	Altered Expression	[7]
ADRA1A	TTNGILX	Strong	Genetic Variation	[2]
ADRA2B	TTWM4TY	Strong	Genetic Variation	[2]
BRD9	TTR7L5Y	Strong	Biomarker	[8]
BRS3	TTKYEPM	Strong	Genetic Variation	[2]
CDC25B	TTR0SWN	Strong	Altered Expression	[9]
CXCR6	TT2BVUA	Strong	Genetic Variation	[2]
CYSLTR1	TTGKOY9	Strong	Biomarker	[10]
CYSLTR2	TT0PZR5	Strong	Genetic Variation	[10]
DPYSL2	TTZCW3T	Strong	Biomarker	[11]
FABP3	TT3TGLR	Strong	Biomarker	[12]
JAG2	TTOJY1B	Strong	Altered Expression	[13]
LGMN	TTPTWV5	Strong	Altered Expression	[14]
LGR4	TTY6C71	Strong	Biomarker	[15]
LIPG	TTHSZXO	Strong	Biomarker	[16]
LPAR2	TTB7Y8I	Strong	Genetic Variation	[2]
PTP4A3	TT7YM8D	Strong	Altered Expression	[11]
REL	TT1ZCTH	Strong	Altered Expression	[17]
SCN10A	TT90XZ8	Strong	Biomarker	[18]
SSTR1	TTIND6G	Strong	Biomarker	[19]
SSTR4	TTAE1BR	Strong	Genetic Variation	[2]
SSTR5	TT2BC4G	Strong	Biomarker	[19]
TDP1	TT64IHJ	Strong	Biomarker	[3]
TMEM97	TT9NXW4	Strong	Biomarker	[20]
ANXA2R	TTM7D9O	Definitive	Biomarker	[21]
CD47	TT28S46	Definitive	Biomarker	[22]
COASY	TT4YO0Z	Definitive	Altered Expression	[23]
GNRH1	TT0ID4A	Definitive	Altered Expression	[24]
GPRC6A	TTI1PRE	Definitive	Genetic Variation	[2]
HSPB3	TTLH8WG	Definitive	Biomarker	[25]
HTR2B	TT0K1SC	Definitive	Altered Expression	[26]
LPAR3	TTE2YJR	Definitive	Genetic Variation	[2]
MRGPRX1	TTIX6PK	Definitive	Genetic Variation	[2]
NME1	TTDY8JH	Definitive	Biomarker	[27]
OXER1	TT7WBSV	Definitive	Genetic Variation	[2]
SSTR2	TTZ6T9E	Definitive	Altered Expression	[19]
SULF2	TTLQTHB	Definitive	Altered Expression	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 42 DTT(s)

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
WARS1	DEPVE0M	Definitive	Altered Expression	[29]
WARS2	DEPTKBQ	Definitive	Altered Expression	[29]
------------------------------------------------------------------------------------

This Disease Is Related to 75 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AHNAK2	OTD2X4BX	Limited	Altered Expression	[30]
CHAC1	OTJGE772	Limited	Altered Expression	[31]
LRP1B	OT4YZG2N	Limited	Genetic Variation	[3]
MUC13	OTWKS9MF	Limited	Biomarker	[32]
OCA2	OTDWIGBF	Limited	Genetic Variation	[33]
OCM	OTQRML29	Limited	Biomarker	[34]
PLCB4	OTPA0QHW	Limited	Genetic Variation	[35]
RASGRP3	OTEMEV3P	Limited	Biomarker	[36]
STAP1	OTUTZH0W	Limited	Genetic Variation	[3]
RTL1	OTOT33IM	Disputed	Biomarker	[6]
ANKRD36B	OT3MW415	moderate	Biomarker	[37]
CNKSR3	OTXP4QH8	moderate	Altered Expression	[38]
S100A2	OTTGHJ1H	moderate	Biomarker	[39]
TNFRSF10D	OTOSRDJT	moderate	Biomarker	[40]
ABTB1	OTKKPQJL	Strong	Biomarker	[41]
ADA2	OTGCV24S	Strong	Biomarker	[42]
ADPRHL1	OTHKQ4K4	Strong	Biomarker	[41]
ARF6	OTVV7KJO	Strong	Biomarker	[43]
ATG12	OTJRO09Y	Strong	Biomarker	[21]
ATN1	OTNZFLKY	Strong	Biomarker	[44]
BRAP	OTB7BAFQ	Strong	Genetic Variation	[45]
BTNL2	OTTTEMZA	Strong	Genetic Variation	[46]
BTNL9	OT3PWOH6	Strong	Biomarker	[47]
CANT1	OT1TPWQR	Strong	Biomarker	[48]
CENPS	OTZ4J391	Strong	Biomarker	[49]
CIITA	OTRJNZFO	Strong	Altered Expression	[50]
CLPTM1L	OTDJWQXI	Strong	Genetic Variation	[3]
CTDSPL	OTZJ0CZK	Strong	Biomarker	[51]
DDX43	OTK1RYSK	Strong	Altered Expression	[52]
DLK2	OT56Y83S	Strong	Genetic Variation	[53]
EIF1	OTB4GZ0V	Strong	Genetic Variation	[54]
EIF1AX	OTWG2LAB	Strong	Genetic Variation	[54]
GAB2	OTBFN705	Strong	Altered Expression	[55]
GDF11	OTOSNMND	Strong	Altered Expression	[56]
GPR42	OTEB0ROY	Strong	Genetic Variation	[2]
GTF2H4	OTPD1DIU	Strong	Biomarker	[57]
JMJD6	OTILR7E4	Strong	Biomarker	[58]
KCTD12	OTPYKT4Z	Strong	Altered Expression	[59]
KIF15	OTJRJEXL	Strong	Biomarker	[60]
KTN1	OTQAV541	Strong	Genetic Variation	[53]
LBH	OT87AT1X	Strong	Biomarker	[61]
MAGI1	OTMV4ASV	Strong	Biomarker	[62]
NAE1	OTMC6F3Y	Strong	Altered Expression	[44]
PHB2	OTCAX3AW	Strong	Biomarker	[45]
PHF10	OTWDR4EX	Strong	Biomarker	[63]
PRDX3	OTLB2WEU	Strong	Biomarker	[64]
PRX	OT34Z10B	Strong	Biomarker	[65]
RAB31	OTMLXQZ0	Strong	Biomarker	[66]
RAB8A	OTPB54Y3	Strong	Biomarker	[67]
RASSF1	OTEZIPB7	Strong	Posttranslational Modification	[68]
RELB	OTU3QYEF	Strong	Altered Expression	[57]
RHPN1	OTYZ1NV8	Strong	Biomarker	[69]
RNF2	OTFPLOIN	Strong	Biomarker	[62]
RPL13A	OTME3VXN	Strong	Altered Expression	[70]
SDCBP	OTS3NCC5	Strong	Altered Expression	[71]
SEM1	OTASLBM1	Strong	Biomarker	[68]
SIL1	OTDI85I5	Strong	Biomarker	[45]
SPANXA1	OTMK3QIS	Strong	Altered Expression	[72]
SPANXC	OT1033B9	Strong	Altered Expression	[72]
SPANXD	OTMM6ANB	Strong	Altered Expression	[72]
TRIO	OT71X1AK	Strong	Biomarker	[73]
CDC42EP3	OTUZ3U9Z	Definitive	Genetic Variation	[74]
EFS	OT06O7XL	Definitive	Biomarker	[68]
FZD4	OTGLZIE0	Definitive	Genetic Variation	[2]
GPR151	OT7EACU6	Definitive	Genetic Variation	[2]
HSPB2	OTS01646	Definitive	Biomarker	[25]
LGR6	OTPZ1PWR	Definitive	Genetic Variation	[2]
MBD4	OTWR9YXE	Definitive	Biomarker	[75]
MRGPRX3	OTRKCCDS	Definitive	Genetic Variation	[2]
MRGPRX4	OTOBHZVA	Definitive	Genetic Variation	[2]
PERP	OTP0YL53	Definitive	Biomarker	[76]
RASEF	OTGSAM2E	Definitive	Biomarker	[68]
SMR3B	OTL5HNM8	Definitive	Altered Expression	[11]
SOX10	OTF25ULQ	Definitive	Altered Expression	[77]
SRSF2	OTVDHO6U	Definitive	Genetic Variation	[78]
------------------------------------------------------------------------------------


⏷ Show the Full List of 75 DOT(s)

References

1	ClinicalTrials.gov (NCT05022901) An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma. U.S.National Institutes of Health.
2	Atypical activation of the G protein G(q) by the oncogenic mutation Q209P.J Biol Chem. 2018 Dec 21;293(51):19586-19599. doi: 10.1074/jbc.RA118.005291. Epub 2018 Oct 23.
3	Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1.Melanoma Res. 2020 Apr;30(2):166-172. doi: 10.1097/CMR.0000000000000641.
4	Decitabine limits escape from MEK inhibition in uveal melanoma.Pigment Cell Melanoma Res. 2020 May;33(3):507-514. doi: 10.1111/pcmr.12849. Epub 2019 Dec 6.
5	Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression.Melanoma Res. 2010 Aug;20(4):303-10. doi: 10.1097/CMR.0b013e32833906e3.
6	Targeted silencing of MART-1 gene expression by RNA interference enhances the migration ability of uveal melanoma cells.Int J Mol Sci. 2013 Jul 19;14(7):15092-104. doi: 10.3390/ijms140715092.
7	Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.Peptides. 2014 May;55:1-12. doi: 10.1016/j.peptides.2014.01.030. Epub 2014 Feb 15.
8	Spliceosomal disruption of the non-canonical BAF complex in cancer.Nature. 2019 Oct;574(7778):432-436. doi: 10.1038/s41586-019-1646-9. Epub 2019 Oct 9.
9	Identification of differentially expressed genes and functional annotations associated with metastases of the uveal melanoma.J Cell Biochem. 2019 Nov;120(11):19202-19214. doi: 10.1002/jcb.29250. Epub 2019 Jul 3.
10	Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.Ophthalmic Res. 2020;63(3):358-368. doi: 10.1159/000502888. Epub 2019 Oct 15.
11	Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2.Sci Rep. 2019 Feb 28;9(1):2990. doi: 10.1038/s41598-019-39643-y.
12	Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.Invest Ophthalmol Vis Sci. 2012 Jul 9;53(8):4634-43. doi: 10.1167/iovs.11-9019.
13	A role for Jag2 in promoting uveal melanoma dissemination and growth.Invest Ophthalmol Vis Sci. 2013 Jan 9;54(1):295-306. doi: 10.1167/iovs.12-10209.
14	Prognostic value of legumain in uveal melanoma.Mol Med Rep. 2016 Mar;13(3):2377-84. doi: 10.3892/mmr.2016.4838. Epub 2016 Jan 29.
15	The Interplay of MicroRNA-34a, LGR4, EMT-Associated Factors, and MMP2 in Regulating Uveal Melanoma Cells.Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4503-4510. doi: 10.1167/iovs.18-26477.
16	Mitochondrial disorders and the eye.Curr Opin Ophthalmol. 2011 Sep;22(5):325-31. doi: 10.1097/ICU.0b013e328349419d.
17	Constitutive expression of c-REL in uveal melanoma patients: correlation with clinicopathological parameters and patient outcome.Clin Transl Oncol. 2020 Jul;22(7):1193-1204. doi: 10.1007/s12094-019-02247-z. Epub 2019 Nov 25.
18	Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.Mol Cancer. 2019 Sep 16;18(1):140. doi: 10.1186/s12943-019-1070-7.
19	Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.Molecules. 2018 Jun 26;23(7):1535. doi: 10.3390/molecules23071535.
20	Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma.Oncotarget. 2017 Jul 25;8(53):91099-91111. doi: 10.18632/oncotarget.19556. eCollection 2017 Oct 31.
21	ZNNT1 long noncoding RNA induces autophagy to inhibit tumorigenesis of uveal melanoma by regulating key autophagy gene expression.Autophagy. 2020 Jul;16(7):1186-1199. doi: 10.1080/15548627.2019.1659614. Epub 2019 Sep 3.
22	Differential modulation and prognostic values of immune-escape genes in uveal melanoma.PLoS One. 2019 Jan 17;14(1):e0210276. doi: 10.1371/journal.pone.0210276. eCollection 2019.
23	GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.Medicine (Baltimore). 2016 Jan;95(4):e2336. doi: 10.1097/MD.0000000000002336.
24	Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).Eur J Pharm Sci. 2018 Oct 15;123:371-376. doi: 10.1016/j.ejps.2018.08.002. Epub 2018 Aug 2.
25	A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma.Clin Proteomics. 2019 Mar 5;16:10. doi: 10.1186/s12014-019-9230-8. eCollection 2019.
26	Analysis of the proteasome activity and the turnover of the serotonin receptor 2B (HTR2B) in human uveal melanoma.Exp Eye Res. 2019 Jul;184:72-77. doi: 10.1016/j.exer.2019.04.013. Epub 2019 Apr 16.
27	Expression of nm23-H1 in uveal melanoma.Melanoma Res. 2007 Oct;17(5):284-90. doi: 10.1097/CMR.0b013e3282eeea5a.
28	SULFs in human neoplasia: implication as progression and prognosis factors.J Transl Med. 2011 May 21;9:72. doi: 10.1186/1479-5876-9-72.
29	Tryptophanyl-tRNA synthetase (WARS) expression in uveal melanoma - possible contributor during uveal melanoma progression.Biosci Biotechnol Biochem. 2020 Mar;84(3):471-480. doi: 10.1080/09168451.2019.1686967. Epub 2019 Nov 6.
30	AHNAK Nucleoprotein 2 Performs a Promoting Role in the Proliferation and Migration of Uveal Melanoma Cells.Cancer Biother Radiopharm. 2019 Dec;34(10):626-633. doi: 10.1089/cbr.2019.2778. Epub 2019 Oct 17.
31	Higher expression of cation transport regulator-like protein 1 (CHAC1) predicts of poor outcomes in uveal melanoma (UM) patients.Int Ophthalmol. 2019 Dec;39(12):2825-2832. doi: 10.1007/s10792-019-01129-1. Epub 2019 Jun 3.
32	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases.Clin Chem Lab Med. 2018 Oct 25;56(11):1945-1953. doi: 10.1515/cclm-2018-0139.
33	A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus.NPJ Genom Med. 2017;2:5. doi: 10.1038/s41525-017-0008-5. Epub 2017 Mar 10.
34	Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines.Onco Targets Ther. 2018 Feb 22;11:933-941. doi: 10.2147/OTT.S148174. eCollection 2018.
35	Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma.Cancers (Basel). 2019 Oct 30;11(11):1688. doi: 10.3390/cancers11111688.
36	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.Cell Rep. 2018 Feb 27;22(9):2455-2468. doi: 10.1016/j.celrep.2018.01.081.
37	An ocular melanoma-associated antigen. Molecular characterization.Arch Ophthalmol. 1992 Mar;110(3):399-404. doi: 10.1001/archopht.1992.01080150097036.
38	Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival.Am J Pathol. 2013 Mar;182(3):678-87. doi: 10.1016/j.ajpath.2012.11.036. Epub 2013 Jan 26.
39	Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells. Clin Cancer Res. 2007 Sep 1;13(17):5219-25. doi: 10.1158/1078-0432.CCR-07-0816.
40	Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma.Biochem Biophys Res Commun. 2013 Nov 29;441(4):743-50. doi: 10.1016/j.bbrc.2013.10.114. Epub 2013 Nov 5.
41	Co-expression modules construction by WGCNA and identify potential prognostic markers of uveal melanoma.Exp Eye Res. 2018 Jan;166:13-20. doi: 10.1016/j.exer.2017.10.007. Epub 2017 Oct 12.
42	Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts.Pigment Cell Melanoma Res. 2017 May;30(3):317-327. doi: 10.1111/pcmr.12577. Epub 2017 Apr 19.
43	ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma.Cancer Cell. 2016 Jun 13;29(6):889-904. doi: 10.1016/j.ccell.2016.04.015. Epub 2016 Jun 2.
44	Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma.Clin Cancer Res. 2018 Aug 1;24(15):3741-3754. doi: 10.1158/1078-0432.CCR-17-1703. Epub 2017 Dec 12.
45	PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma.Cancers (Basel). 2019 May 29;11(6):751. doi: 10.3390/cancers11060751.
46	Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma.JAMA Ophthalmol. 2016 Oct 1;134(10):1125-1133. doi: 10.1001/jamaophthalmol.2016.2691.
47	Butyrophilin-Like 9 (BTNL9) Suppresses Invasion and Correlates with Favorable Prognosis of Uveal Melanoma.Med Sci Monit. 2019 Apr 30;25:3190-3198. doi: 10.12659/MSM.914074.
48	CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma.Mol Ther. 2017 May 3;25(5):1209-1221. doi: 10.1016/j.ymthe.2017.02.016. Epub 2017 Mar 18.
49	Expression of APITD1 is not related to copy number changes of chromosomal region 1p36 or the prognosis of uveal melanoma.Invest Ophthalmol Vis Sci. 2007 Nov;48(11):4919-23. doi: 10.1167/iovs.07-0061.
50	A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.J Immunol. 2007 Oct 15;179(8):5317-25. doi: 10.4049/jimmunol.179.8.5317.
51	The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma.J Exp Clin Cancer Res. 2018 Jan 30;37(1):15. doi: 10.1186/s13046-018-0679-5.
52	Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.Mol Cancer Ther. 2014 Aug;13(8):2073-80. doi: 10.1158/1535-7163.MCT-14-0095. Epub 2014 Jun 4.
53	Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.Am J Hum Genet. 2016 Nov 3;99(5):1190-1198. doi: 10.1016/j.ajhg.2016.09.008. Epub 2016 Oct 13.
54	eIF1A residues implicated in cancer stabilize translation preinitiation complexes and favor suboptimal initiation sites in yeast.Elife. 2017 Dec 5;6:e31250. doi: 10.7554/eLife.31250.
55	Grb2-associated binder 2 expression and its roles in uveal melanoma invasion.Mol Med Rep. 2017 Oct;16(4):4577-4582. doi: 10.3892/mmr.2017.7151. Epub 2017 Aug 3.
56	GDF11 upregulation independently predicts shorter overall-survival of uveal melanoma.PLoS One. 2019 Mar 18;14(3):e0214073. doi: 10.1371/journal.pone.0214073. eCollection 2019.
57	Differential expression of p52 and RelB proteins in the metastatic and non-metastatic groups of uveal melanoma with patient outcome.J Cancer Res Clin Oncol. 2019 Dec;145(12):2969-2982. doi: 10.1007/s00432-019-03052-5. Epub 2019 Oct 14.
58	KRas-ERK signalling promotes the onset and maintenance of uveal melanoma through regulating JMJD6-mediated H2A.X phosphorylation at tyrosine 39.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4257-4265. doi: 10.1080/21691401.2019.1673764.
59	Lentiviral-mediated overexpression of KCTD12 inhibits the proliferation of human uveal melanoma OCM-1 cells.Oncol Rep. 2017 Feb;37(2):871-878. doi: 10.3892/or.2016.5325. Epub 2016 Dec 16.
60	KIF15 plays a role in promoting the tumorigenicity of melanoma.Exp Eye Res. 2019 Aug;185:107598. doi: 10.1016/j.exer.2019.02.014. Epub 2019 Feb 21.
61	The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.Anticancer Res. 2018 Jul;38(7):3817-3824. doi: 10.21873/anticanres.12665.
62	Density of PAS positive patterns in uveal melanoma: Correlation with vasculogenic mimicry, gene expression class, BAP-1 expression, macrophage infiltration, and risk for metastasis.Mol Vis. 2019 Sep 21;25:502-516. eCollection 2019.
63	Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for PHF10/BAF45a.Clin Cancer Res. 2019 Aug 15;25(16):5156-5166. doi: 10.1158/1078-0432.CCR-18-3052. Epub 2019 Jun 21.
64	PRDX3 is associated with metastasis and poor survival in uveal melanoma.J Clin Pathol. 2020 Jul;73(7):408-412. doi: 10.1136/jclinpath-2019-206173. Epub 2019 Nov 26.
65	Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.Clin Exp Metastasis. 2018 Mar;35(3):123-134. doi: 10.1007/s10585-018-9894-x. Epub 2018 Apr 25.
66	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders.Sci Rep. 2017 Sep 18;7(1):11762. doi: 10.1038/s41598-017-12084-1.
67	Autocrine impact of VEGF-A on uveal melanoma cells.Invest Ophthalmol Vis Sci. 2014 Apr 25;55(4):2697-704. doi: 10.1167/iovs.13-13254.
68	DNA Methylation and Uveal Melanoma.Chin Med J (Engl). 2018 Apr 5;131(7):845-851. doi: 10.4103/0366-6999.228229.
69	The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression.Int J Mol Sci. 2017 Jan 23;18(1):226. doi: 10.3390/ijms18010226.
70	Expression profiling of formalin-fixed paraffin embedded primary human uveal melanomas using DASL matrices.J Cancer Res Clin Oncol. 2010 Apr;136(4):577-86. doi: 10.1007/s00432-009-0692-3. Epub 2009 Oct 13.
71	Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.PLoS One. 2012;7(1):e29989. doi: 10.1371/journal.pone.0029989. Epub 2012 Jan 13.
72	Immunoexpression of SPANX-C in metastatic uveal melanoma.Pathol Res Pract. 2019 Jul;215(7):152431. doi: 10.1016/j.prp.2019.04.023. Epub 2019 Apr 29.
73	A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.Cancer Cell. 2019 Mar 18;35(3):457-472.e5. doi: 10.1016/j.ccell.2019.01.009. Epub 2019 Feb 14.
74	Genomic microarray analysis on formalin-fixed paraffin-embedded material for uveal melanoma prognostication.Cancer Genet. 2014 Jul-Aug;207(7-8):306-15. doi: 10.1016/j.cancergen.2014.08.005. Epub 2014 Aug 29.
75	Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab.Immunogenetics. 2019 May;71(5-6):433-436. doi: 10.1007/s00251-019-01108-x. Epub 2019 Feb 4.
76	p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma.Br J Cancer. 2016 Oct 11;115(8):983-992. doi: 10.1038/bjc.2016.269. Epub 2016 Sep 1.
77	SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5445-5451. doi: 10.1167/iovs.17-22362.
78	SRSF2 Mutations in Uveal Melanoma: A Preference for In-Frame Deletions?.Cancers (Basel). 2019 Aug 17;11(8):1200. doi: 10.3390/cancers11081200.